Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid TumorsMartina S.J. McDermott, Dennis J. Slamon|Clinical Cancer Research|2023Cited by 48
PP2A inhibition overcomes acquired resistance to HER2 targeted therapyMartina S.J. McDermott, Norma O’Donovan|Molecular Cancer|2014Cited by 42